ARRY-797
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555466

CAS#: 1036404-17-7

Description: ARRY-797, also known as ARRY-371797, is a potent and selective p38α inhibitor (p38 mitogen-activated protein kinase inhibitor). ARRY-371797 Inhibits LPS-Induced IL-6 and In Vivo Growth of RPMI-8226 Human Multiple Myeloma Cells.


Price and Availability

Size
Price

5mg
USD 150
50mg
USD 750
500mg
USD 2250
Size
Price

10mg
USD 250
100mg
USD 1050
1g
USD 3450
Size
Price

25mg
USD 450
200mg
USD 1650
2g
USD 4650

ARRY-797, purity > 98%, is in stock. The same day shipping out after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 555466
Name: ARRY-797
CAS#: 1036404-17-7
Chemical Formula: C22H26F2N4O2
Exact Mass: 416.2024
Molecular Weight: 416.4728
Elemental Analysis: C, 63.45; H, 6.29; F, 9.12; N, 13.45; O, 7.68


Synonym: ARRY-371797; ARRY 371797; ARRY371797; ARRY-797; ARRY 797; ARRY797;

IUPAC/Chemical Name: 5-(2,4-difluorophenoxy)-N-(2-(dimethylamino)ethyl)-1-isobutyl-1H -indazole-6-carboxamide

InChi Key: IFGWYHGYNVGVRB-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H26F2N4O2/c1-14(2)13-28-19-11-17(22(29)25-7-8-27(3)4)21(9-15(19)12-26-28)30-20-6-5-16(23)10-18(20)24/h5-6,9-12,14H,7-8,13H2,1-4H3,(H,25,29)

SMILES Code: O=C(C1=CC2=C(C=C1OC3=CC=C(F)C=C3F)C=NN2CC(C)C)NCCN(C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934990300


Additional Information

directly inhibited LPS-induced IL-6 production from RPMI-8226 (IC50 = 100 pM) in vitro. In SCID-beige mice, LPS (3 μg/kg) induced IL-6 (7897 ± 827 pg/mL) and TNF-alpha (1922 ± 282 pg/mL) after 2 hours and these cytokines were inhibited by oral administration of ARRY-797 (30 mg/kg) by 91% and 95%, respectively. In MM xenograft models, ARRY-797 (30 mg/kg, BID, PO) inhibited RPMI 8226 tumor growth by 72% as a single agent and by 56% when LPS was administered to stimulate growth in vivo. In addition, ARRY-797 inhibited LPS-induced phosphorylation of p38 in RPMI-8226 xenografts. Together, these data support a role for p38 in IL-6-mediated growth of multiple myelomas. ARRY-797 is the first small molecule p38 inhibitor to demonstrate single agent activity in a MM xenograft model and it has been advanced into preclinical development.


References

1: Carter D, Warsen A, Mandell K, Cuschieri J, Maier RV, Arbabi S. Delayed topical p38 MAPK inhibition attenuates full-thickness burn wound inflammatory
signaling. J Burn Care Res. 2014 Mar-Apr;35(2):e83-92. doi: 10.1097/BCR.0b013e31828a8d6e. PubMed PMID: 23666384; PubMed Central PMCID: PMC4180234.

2: Muchir A, Wu W, Choi JC, Iwata S, Morrow J, Homma S, Worman HJ. Abnormal p38α mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation. Hum Mol Genet. 2012 Oct 1;21(19):4325-33. doi: 10.1093/hmg/dds265. Epub 2012 Jul 5. PubMed PMID: 22773734; PubMed Central PMCID: PMC3441127.

3. http://www.bloodjournal.org/content/108/11/3478?sso-checked=true